Survival determinants in extensive-stage non-small-cell lung cancer: The southwest oncology group experience

Kathy S. Albain, John J. Crowley, Michael LeBlanc, Robert B Livingston

Research output: Contribution to journalArticle

627 Citations (Scopus)

Abstract

We analyzed the 2,531-patient Southwest Oncology Group extensive-stage non-small-cell lung cancer (EN-SCLC) data base from 1974 to 1988 to (1) assess the interactions of host- or tumor-related prognostic factors and therapy using Cox modeling and recursive partitioning and amalgamation (RPA) to determine whether each independently predicts outcome, and (2) use RPA to define prognostic subsets with different survival potentials. Good performance status (PS), female sex, and age ≥ 70 years were significant independent predictors in a Cox model applied to the entire population. In a second Cox model for patients with good PS enrolled on recent studies, hemoglobin level ≥ 11.0 g/dL, normal lactate dehydrogenase (LDH), normal calcium, and a single metastatic site were significant favorable factors. The use of cisplatin was an additional independent predictor of improved outcome in both Cox models after adjustments for year of accrual and all prognostic variables. The favorable effect of cisplatin was observed in each of six RPA-derived subgroups from the entire population. A second RPA of 904 patients from recent trials (nearly all received cisplatin-based therapy) resulted in three distinct prognostic subsets based on PS, age, hemoglobin, and LDH; ≥ 1-year survivals were 27%, 16%, and 6% (P < .0001). The best survival occurred for patients with a good PS who had a hemoglobin level ≥ 11 g/dL and who were older than 47 years. This analysis suggests that although several factors were independent variables in the Cox models, three important prognostic subgroups were easily defined through RPA. Together with other analyses, our results suggest the need to modify the stage IV category in NSCLC.

Original languageEnglish (US)
Pages (from-to)1618-1626
Number of pages9
JournalJournal of Clinical Oncology
Volume9
Issue number9
StatePublished - Sep 1991
Externally publishedYes

Fingerprint

Proportional Hazards Models
Non-Small Cell Lung Carcinoma
Cisplatin
Hemoglobins
Survival
L-Lactate Dehydrogenase
Population
Databases
Calcium
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Survival determinants in extensive-stage non-small-cell lung cancer : The southwest oncology group experience. / Albain, Kathy S.; Crowley, John J.; LeBlanc, Michael; Livingston, Robert B.

In: Journal of Clinical Oncology, Vol. 9, No. 9, 09.1991, p. 1618-1626.

Research output: Contribution to journalArticle

@article{9782eb7f0113443986099d846939d27b,
title = "Survival determinants in extensive-stage non-small-cell lung cancer: The southwest oncology group experience",
abstract = "We analyzed the 2,531-patient Southwest Oncology Group extensive-stage non-small-cell lung cancer (EN-SCLC) data base from 1974 to 1988 to (1) assess the interactions of host- or tumor-related prognostic factors and therapy using Cox modeling and recursive partitioning and amalgamation (RPA) to determine whether each independently predicts outcome, and (2) use RPA to define prognostic subsets with different survival potentials. Good performance status (PS), female sex, and age ≥ 70 years were significant independent predictors in a Cox model applied to the entire population. In a second Cox model for patients with good PS enrolled on recent studies, hemoglobin level ≥ 11.0 g/dL, normal lactate dehydrogenase (LDH), normal calcium, and a single metastatic site were significant favorable factors. The use of cisplatin was an additional independent predictor of improved outcome in both Cox models after adjustments for year of accrual and all prognostic variables. The favorable effect of cisplatin was observed in each of six RPA-derived subgroups from the entire population. A second RPA of 904 patients from recent trials (nearly all received cisplatin-based therapy) resulted in three distinct prognostic subsets based on PS, age, hemoglobin, and LDH; ≥ 1-year survivals were 27{\%}, 16{\%}, and 6{\%} (P < .0001). The best survival occurred for patients with a good PS who had a hemoglobin level ≥ 11 g/dL and who were older than 47 years. This analysis suggests that although several factors were independent variables in the Cox models, three important prognostic subgroups were easily defined through RPA. Together with other analyses, our results suggest the need to modify the stage IV category in NSCLC.",
author = "Albain, {Kathy S.} and Crowley, {John J.} and Michael LeBlanc and Livingston, {Robert B}",
year = "1991",
month = "9",
language = "English (US)",
volume = "9",
pages = "1618--1626",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Survival determinants in extensive-stage non-small-cell lung cancer

T2 - The southwest oncology group experience

AU - Albain, Kathy S.

AU - Crowley, John J.

AU - LeBlanc, Michael

AU - Livingston, Robert B

PY - 1991/9

Y1 - 1991/9

N2 - We analyzed the 2,531-patient Southwest Oncology Group extensive-stage non-small-cell lung cancer (EN-SCLC) data base from 1974 to 1988 to (1) assess the interactions of host- or tumor-related prognostic factors and therapy using Cox modeling and recursive partitioning and amalgamation (RPA) to determine whether each independently predicts outcome, and (2) use RPA to define prognostic subsets with different survival potentials. Good performance status (PS), female sex, and age ≥ 70 years were significant independent predictors in a Cox model applied to the entire population. In a second Cox model for patients with good PS enrolled on recent studies, hemoglobin level ≥ 11.0 g/dL, normal lactate dehydrogenase (LDH), normal calcium, and a single metastatic site were significant favorable factors. The use of cisplatin was an additional independent predictor of improved outcome in both Cox models after adjustments for year of accrual and all prognostic variables. The favorable effect of cisplatin was observed in each of six RPA-derived subgroups from the entire population. A second RPA of 904 patients from recent trials (nearly all received cisplatin-based therapy) resulted in three distinct prognostic subsets based on PS, age, hemoglobin, and LDH; ≥ 1-year survivals were 27%, 16%, and 6% (P < .0001). The best survival occurred for patients with a good PS who had a hemoglobin level ≥ 11 g/dL and who were older than 47 years. This analysis suggests that although several factors were independent variables in the Cox models, three important prognostic subgroups were easily defined through RPA. Together with other analyses, our results suggest the need to modify the stage IV category in NSCLC.

AB - We analyzed the 2,531-patient Southwest Oncology Group extensive-stage non-small-cell lung cancer (EN-SCLC) data base from 1974 to 1988 to (1) assess the interactions of host- or tumor-related prognostic factors and therapy using Cox modeling and recursive partitioning and amalgamation (RPA) to determine whether each independently predicts outcome, and (2) use RPA to define prognostic subsets with different survival potentials. Good performance status (PS), female sex, and age ≥ 70 years were significant independent predictors in a Cox model applied to the entire population. In a second Cox model for patients with good PS enrolled on recent studies, hemoglobin level ≥ 11.0 g/dL, normal lactate dehydrogenase (LDH), normal calcium, and a single metastatic site were significant favorable factors. The use of cisplatin was an additional independent predictor of improved outcome in both Cox models after adjustments for year of accrual and all prognostic variables. The favorable effect of cisplatin was observed in each of six RPA-derived subgroups from the entire population. A second RPA of 904 patients from recent trials (nearly all received cisplatin-based therapy) resulted in three distinct prognostic subsets based on PS, age, hemoglobin, and LDH; ≥ 1-year survivals were 27%, 16%, and 6% (P < .0001). The best survival occurred for patients with a good PS who had a hemoglobin level ≥ 11 g/dL and who were older than 47 years. This analysis suggests that although several factors were independent variables in the Cox models, three important prognostic subgroups were easily defined through RPA. Together with other analyses, our results suggest the need to modify the stage IV category in NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=0025826624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025826624&partnerID=8YFLogxK

M3 - Article

C2 - 1651993

AN - SCOPUS:0025826624

VL - 9

SP - 1618

EP - 1626

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -